New Zealand Patient Advocates Demand Operational Budget Boost to Resolve Chronic Pharmac Medicine Funding Backlogs

New report warns Pharmac needs more operational funding and staff to speed up New Zealand’s drug access as advocates cite persistent health outcome gaps.

By: AXL Media

Published: Apr 1, 2026, 4:11 PM EDT

Source: Information for this report was sourced from RNZ

Structural Gaps Persist in the National Medicine Pipeline

The release of the "Valuing Life, Medicines Access Summit 2025 Report" has brought renewed scrutiny to the operational constraints of Pharmac, New Zealand's drug funding agency. Compiled by Patient Voice Aotearoa and Medicines New Zealand, the document synthesizes findings from a high level parliamentary summit held in late 2025. Despite a series of recent funding uplifts, the report contends that the agency's delivery remains uneven, with several essential reforms yet to be fully implemented. Advocates suggest that without a fundamental shift toward valuing health outcomes over mere fiscal efficiency, the system will continue to struggle with significant wait times for life saving treatments.

The Urgent Requirement for Specialized Human Capital

Dr. Malcolm Mulholland, chair of Patient Voice Aotearoa, emphasizes that the bottleneck in drug approvals is largely a matter of internal capacity. According to Mulholland, speeding up the health technology assessment process is impossible without a larger operational budget to hire more specialized staff. While the agency has recently recruited additional health economists to bolster its assessment capabilities, the current backlog suggests that human resource levels remain insufficient. Mulholland argues that the operations budget is the most critical factor in ensuring that Pharmac can be as open and responsive as the patient community requires during its current structural reset.

Government Defends Recent Fiscal Allocations and Reforms

In response to the report, Associate Health Minister David Seymour maintained that Pharmac is moving in a positive direction for the first time in years. The government has committed a total budget of $6.294 billion over a four year period, which includes a $604 million increase specifically aimed at widening access to medicines. According to Seymour, this financial injection has already facilitated 133 funding decisions, including access to 46 different cancer treatments that have benefited over 200,000 patients. Seymour noted that the relationship between the government and patient groups has transitioned from public protests to genuine collaborative conversations about service delivery.